UK’s Biotecnol strikes a deal with CRUK to move new immuno-oncology drug into PhI
London-based Biotecnol has struck a deal with Cancer Research UK to move its lead immune-oncology drug into an open-label Phase I test. The pact lends the biotech CRUK’s help in seeing whether its antibody drug Tb535H works as planned: binding to a target antigen and then whipping up an immune response to attack cancer cells.
The drug strategy is simple. Their antibody is designed to latch on to a protein: the 5T4/WAIF1 tumor antigen. That in turn is supposed to flag an assault by CD8-positive T cells, the kind of primary immune tactic that has been driving a wide range of development projects in the cancer field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
